EMEA-000069-PIP05-16
Key facts
| Invented name |
Nucala
|
| Active substance |
Mepolizumab
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0119/2017
|
| PIP number |
EMEA-000069-PIP05-16
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of nasal polyposis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
GSK Trading Services Limited
|
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|